A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

NCT00937352 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

896

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Bapineuzumab

Sponsor

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Collaborators

[object Object]